Sector consensus Unicycive Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-08-25 EDT			5-day change	1st Jan Change
5.470 ^USD	+2.43%		-2.84%	-5.20%

08-13	B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating	MT
08-12	Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Average Target P.	Objective/dr gap	Nbr of analysts
UNICYCIVE THERAPEUTICS, INC.		28.22	+415.95%	9
WUXI APPTEC CO., LTD.		182.53	+13.38%	18
ARGENX SE	-	1,095.01	+6.72%	15
BIONTECH SE		103.92	+6.33%	20
INSMED INCORPORATED		200.18	+61.58%	22
WUXI BIOLOGICS (CAYMAN) INC.		41.74	-6.74%	23
GENMAB A/S		2,410.46	+9.77%	15
PHARMAESSENTIA CORPORATION		1,341.89	-9.94%	8
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		614.54	+17.39%	18
EXELIXIS, INC.		53	-6.56%	17
ARROWHEAD PHARMACEUTICALS, INC.		110.18	+23.97%	11
MADRIGAL PHARMACEUTICALS, INC.		678.06	+32.39%	16
CYTOKINETICS, INCORPORATED		109.9	+41.88%	20
AKESO, INC.		144.2	+88.52%	21
SUMMIT THERAPEUTICS INC.		21.08	+115.18%	13
SPYRE THERAPEUTICS, INC.		123.43	+14.97%	14
VAXCYTE, INC.		109	+78.43%	9
CRINETICS PHARMACEUTICALS, INC.		85.5	+0.75%	10
REMEGEN CO., LTD.		102.35	+48.65%	16
IMMUNITYBIO, INC.		12.75	+55.68%	4
Average		378.4	+50.41%	15
Weighted average by Cap.		500.3	+21.44%	16